PNC-27
A cancer-fighting peptide that works like a smart missile—it hunts down and destroys cancer cells by poking holes in them, while leaving your healthy cells completely untouched.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Typical dose
1–2 mg
Compound profile
Scientific & efficacy data
Immune
Peptide profile
Strong preclinical
PNC-27
1–2 mg · Once daily
Molecular formula
C188H293N53O44S
- Mol. weight
- 4031.73 g/mol
- CAS number
- 1159861-00-3
- PubChem
- 505189537
- Developed · 2006
- Matthew R. Pincus, MD, PhD
SUNY Downstate Medical Center & VA New York Harbor Healthcare System
Amino acid sequence
Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-GlyCancer Cell Selectivity
Exclusively targets cancer cells displaying HDM-2 on their surface while completely ignoring healthy cells—demonstrated in every preclinical study
Rapid Action
Kills cancer cells within 4 hours through direct membrane pore formation, faster than most conventional cancer treatments
Broad Spectrum
Effective against multiple cancer types including breast, pancreatic, colon, ovarian, and various leukemias in laboratory studies
Dosing
How much do I take?
Covers timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for cancer research protocols & oncology support research
Best for
Solid Tumor Research
PNC-27 has shown remarkable results against solid tumors in lab studies. It's been tested against breast, pancreatic, colon, and ovarian cancer cells—and in each case, it killed the cancer cells while the healthy cells next to them stayed perfectly fine. That's the holy grail of cancer research.
Leukemia and Blood Cancer Studies
In studies on acute myeloid leukemia (AML), PNC-27 wiped out cancer cells within just 4 hours. It works on several types of leukemia cells (U937, OCI-AML3, HL-60) by targeting a protein that only shows up on cancer cell surfaces. Normal blood cells? Completely unharmed.
Cancer Stem Cell Targeting
Here's where PNC-27 gets really interesting: it can kill cancer stem cells. These are the sneaky cells that often survive chemo and cause cancer to come back. PNC-27 has shown it can destroy CD44+ colon cancer stem cells, which is a big deal for preventing recurrence.
Drug-Resistant Cancer Research
When cancers stop responding to regular chemotherapy, researchers need new approaches. PNC-27 works through a completely different mechanism than traditional chemo drugs, so it may be effective against cancers that have become resistant to other treatments.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare PNC-27 with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Subcutaneous injection · Intravenous injection
Route
Subcutaneous injection (just under the skin)—it's the easiest method for self-administration
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
3 common side effects · 1 serious
Here's the really cool thing about PNC-27: in all the lab and animal studies so far, it ONLY attacks cancer cells.
Normal, healthy cells are completely ignored because they don't have the protein (HDM-2) on their surface that PNC-27 targets. Animal studies using doses up to 40 mg/kg showed tumors shrinking or disappearing with zero damage to normal tissues.
That said, it hasn't been tested in human clinical trials yet, so we're still learning.
The safety data comes from extensive cell studies and animal experiments—not human trials. The science behind why it's selective is solid (cancer cells uniquely express HDM-2 on their surface), but always work with a medical professional when using research compounds.
Common side effects · experienced by some users
Injection site redness
Localized erythema at the injection site is a normal inflammatory response to PNC-27 and the mechanical trauma of injection. Typically appears within 1-2 hours and resolves within 24-48 hours, reflecting immune activation rather than tissue damage.
Management: Rotate injection sites between abdomen, thigh, and upper arm to allow adequate healing time between injections to the same area. Apply ice packs for 10-15 minutes if redness causes discomfort. If redness persists beyond 48 hours, spreads beyond the injection site, develops red streaking, or is accompanied by warmth/drainage, contact your healthcare provider immediately as this may indicate infection.
Mild fatigue
Transient fatigue may occur following PNC-27 injection, particularly during the first 1-2 weeks as the immune system mounts its initial response to the peptide. This typically resolves within 4-6 hours post-injection and reflects physiological adaptation rather than toxicity.
Management: Plan injections for times when you can rest if needed—morning dosing allows observation throughout the day. Maintain optimal hydration and sleep patterns. Avoid strenuous exercise for 2-4 hours post-injection. If fatigue persists beyond 24 hours or intensifies with subsequent doses, notify your healthcare provider as this may indicate dose adjustment is needed.
Localized warmth or tenderness
Local heat and tenderness at the injection site are expected inflammatory responses to PNC-27 administration and represent normal tissue reaction to the peptide. Typically most pronounced in the first 6-12 hours and resolves within 24-48 hours as inflammation subsides.
Management: Apply cool (not cold) compresses for 10-15 minutes several times in the first 24 hours to reduce local inflammation and discomfort. Avoid rubbing or massaging the injection site. Wear loose clothing over the area if pressure bothers you. If warmth persists beyond 48 hours, expands beyond a 2-inch radius from the injection point, or is accompanied by erythema, purulent drainage, or systemic fever, contact your healthcare provider immediately as this may indicate cellulitis or infection.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Any signs of allergic reaction—hives, swelling, trouble breathing (stop immediately and get help)
- Fever that stays above 101°F for more than a day
- Injection site reactions that keep getting worse instead of better
- Any side effect that feels serious or really concerns you
- Your research protocol is complete
- Your supervising doctor or researcher tells you to stop
PNC-27 is a research compound, not an approved medication. Never start, stop, or change your dosing without guidance from a qualified medical professional or research supervisor. This information is for educational purposes—it's not medical advice.
With other peptides
- Safe:BPC-157 — Generally considered safe to use together. BPC-157 supports healing and gut health, which complements PNC-27's targeted approach. Inject at different sites.
- Safe:Thymosin Alpha-1 — May actually work well together since both support immune function in different ways. Thymosin boosts overall immunity while PNC-27 targets cancer cells specifically.
- Safe:GHK-Cu — Safe to combine. GHK-Cu helps with tissue repair and has its own mild anticancer properties. Different mechanisms, so no conflict expected.
- Caution:PNC-28 — Don't use these together. PNC-28 is basically a shorter version of PNC-27 that works the same way. Using both would be redundant and could cause unexpected effects.
With medications
- Caution:Immunosuppressants (like prednisone, cyclosporine) — Could interfere with how PNC-27 works since it relies partly on immune function. Talk to your doctor—you may need to adjust timing or dosing.
- Caution:Blood thinners (warfarin, aspirin, etc.) — May increase bleeding or bruising at injection sites. Not dangerous, but something to watch. Your doctor might want to monitor your clotting levels.
- Safe:NSAIDs (ibuprofen, naproxen) — Generally fine for occasional use. They might slightly increase injection site bleeding but nothing serious for most people.
- Caution:Chemotherapy drugs — Unknown interactions—PNC-27 works differently than chemo, which could be good or bad. Only combine under oncologist supervision in a research setting.
With supplements
- Safe:Vitamin D — Safe and potentially helpful. Vitamin D supports immune function, which could complement PNC-27's effects.
- Safe:Zinc — Safe to take together. Zinc is important for immune health and wound healing from injections.
- Safe:Omega-3 fish oil — Safe to combine. May have mild blood-thinning effects, so watch for extra bruising at injection sites, but nothing dangerous.
- Safe:High-dose antioxidants (vitamin C megadoses, etc.) — Theoretical concern here: PNC-27 kills cancer cells partly through oxidative stress. Flooding your body with antioxidants might interfere. Stick to normal supplement doses.
Effectiveness
How do I know it's working?
Strong preclinical · first signs week 1-2
Evidence level
Strong preclinical
(extensive animal studies)
Regulatory status
Research compound
Onset of effects
Rapid
(hours to days)
How it works
Think of PNC-27 as a smart missile designed to destroy only cancer cells.
It has two parts: a 'finder' part that recognizes a protein called HDM-2 (which cancer cells foolishly display on their outer surface, while healthy cells keep it locked inside), and a 'destroyer' part that punches holes in the cell membrane.
When PNC-27 finds a cancer cell showing HDM-2 on its surface, it latches on and creates tiny pores—like poking holes in a water balloon. The cancer cell's insides leak out and it dies. Healthy cells don't have HDM-2 on their surface, so PNC-27 floats right past them without causing any harm.
The deeper mechanism
PNC-27 is a 32-amino acid chimeric peptide consisting of two functional domains: residues 12-26 from the p53 tumor suppressor protein (which binds to the p53-binding cleft of HDM-2/MDM2) and a membrane residency peptide (MRP) derived from the Antennapedia homeodomain that facilitates membrane integration.
The peptide exploits a unique characteristic of cancer cells—aberrant expression of HDM-2 in plasma membranes rather than its normal intracellular location.
Upon binding to membrane-associated HDM-2, PNC-27 molecules oligomerize into ring-shaped structures approximately 1-2 micrometers in diameter, forming transmembrane pores through a process termed 'poptosis.'
This pore formation causes rapid efflux of cytoplasmic contents and necrotic cell death, typically within 4 hours. Additionally, PNC-27 can penetrate cancer cells and disrupt mitochondrial membranes, providing a secondary killing mechanism.
The selectivity is absolute in preclinical models: cells expressing membrane HDM-2 undergo rapid necrosis, while cells with exclusively intracellular HDM-2 (normal cells) remain completely unaffected.
This mechanism is distinct from apoptosis and bypasses many resistance mechanisms that cancer cells develop against conventional chemotherapy.
What to expect
Week 1-2
What you might notice
- Some redness or tenderness at injection sites (totally normal)
- Maybe a bit of fatigue as your body adjusts
- Possibly nothing at all—many people have no noticeable effects
- In research settings, baseline measurements are being established
What's normal
- Mild injection site reactions that fade within a day or two
- Feeling slightly tired on injection days
- No dramatic changes yet—patience is key
- Your body is getting used to the peptide
What's next
- Keep following your protocol consistently
- Track any side effects in a simple log
- If you're tolerating it well, you may move to a higher dose soon
Week 3-4
What you might notice
- Injection site reactions usually decrease as your body adapts
- In research contexts, early marker changes might start appearing
- You'll likely settle into a routine and injections become easier
- Overall tolerance typically improves
What's normal
- Fewer and milder injection site reactions
- Steady energy levels
- The process feeling more routine and less nerve-wracking
- Mid-protocol assessments happening in research settings
What's next
- Continue with your established routine
- Dose increases happen around now if your protocol calls for it
- Keep tracking any changes or effects
Week 5-6+
What you might notice
- Full adaptation—injections should be pretty routine by now
- In research settings, this is when meaningful data gets collected
- Minimal to no injection site reactions for most people
- Your body has adjusted to the peptide
What's normal
- Smooth sailing with the injection routine
- Stable health markers and energy levels
- Approaching the end of a typical research cycle
- Time for end-of-protocol assessments
What's next
- Complete your protocol as directed
- Work with your supervisor to evaluate results
- Discuss whether to continue, pause, or conclude
Signs it's working
Research/Clinical Markers (in supervised settings)
- Tumor markers trending downward on blood tests
- Imaging scans showing reduced tumor size or activity
- Improved lab values related to your specific condition
- No disease progression during treatment
- Cancer cell counts decreasing (in leukemia research)
Personal Tolerance Indicators
- Side effects decreasing or staying minimal over time
- Energy levels staying stable or improving
- No allergic reactions or concerning symptoms
- Injection sites healing cleanly between doses
- Generally feeling okay throughout the protocol
Not seeing results? Common reasons
- Peptide degraded from improper storage—always check if your solution looks right before injecting (clear, no particles)
- Inconsistent dosing schedule—try to inject at the same time each day for best results
- Using a peptide that sat too long after reconstitution—stick to the 14-day window
- Poor quality peptide from unreliable source—always get third-party testing certificates (COAs)
- Dose too low for your specific research goals—this should be evaluated by your protocol supervisor
- Not enough time on protocol—meaningful results often take the full 4-6 weeks to emerge
Key research
Questions
Frequently asked
How does PNC-27 know which cells are cancerous?
It's all about a protein called HDM-2. In healthy cells, HDM-2 stays inside the cell where it belongs. But cancer cells make a mistake—they put HDM-2 on their outer surface like a flag. PNC-27 is designed to recognize and bind to that flag. No flag on the surface? PNC-27 ignores the cell completely. This is why it can kill cancer cells without harming the healthy ones right next to them.
Is PNC-27 FDA approved?
No, not yet. PNC-27 is currently a research compound that has shown very promising results in lab studies and animal experiments. It hasn't gone through human clinical trials yet, which are required for FDA approval. That's why it's only available for research purposes and should only be used under proper medical or scientific supervision.
What types of cancer has PNC-27 been tested against?
In lab studies, PNC-27 has successfully killed cells from breast cancer, pancreatic cancer, colon cancer, ovarian cancer, and several types of leukemia (AML, acute monocytic leukemia, acute promyelocytic leukemia). It's also been shown to kill cancer stem cells, which is exciting because these cells often survive regular chemotherapy.
How fast does PNC-27 work?
Remarkably fast compared to most cancer treatments. In laboratory studies, PNC-27 killed cancer cells within 4 hours of exposure. It works by physically creating holes in cancer cell membranes, so the effect is pretty immediate once it binds to its target. Of course, shrinking actual tumors in a body takes longer and depends on many factors.
Can I use PNC-27 instead of chemotherapy?
That's not something anyone can recommend right now. PNC-27 hasn't been tested in human clinical trials, so we don't know how it works in actual cancer patients—only in lab dishes and animals. Never replace proven treatments with experimental ones without your oncologist's guidance. PNC-27 might one day be used alongside or instead of chemo, but that's still being researched.
Why haven't I heard of PNC-27 before if it's so promising?
Great science takes time. PNC-27 has been studied since the mid-2000s, and the research is genuinely exciting. But moving from lab success to approved medicine takes years of clinical trials, massive funding, and navigating regulatory hurdles. Many promising compounds are in this 'valley' between lab discovery and clinical use. PNC-27 is working its way through that process.
What's the difference between PNC-27 and PNC-28?
They're cousins, basically. PNC-27 contains p53 residues 12-26, while PNC-28 is shorter with just residues 17-26. Both target HDM-2 on cancer cell membranes, but PNC-27 is generally more potent because it has a longer binding region. Researchers study both to understand which parts of the sequence are most important for killing cancer cells.
Are there any serious risks I should know about?
The biggest risk with any peptide is allergic reaction, though it's rare. In animal studies, PNC-27 showed no damage to normal tissues—which is amazing and unusual for cancer treatments. However, it hasn't been tested in humans yet, so there could be risks we don't know about. That's why medical supervision is absolutely essential.
Further reading
History & related research
History · since 2000
The peptide that selectively destroys cancer cells while leaving healthy cells unharmed
A revolutionary 32-amino acid chimeric peptide designed by computational drug design that exploits cancer cells' aberrant HDM-2 membrane expression. PNC-27 represents the holy grail of cancer therapy—selective destruction of malignant cells with a >100-fold safety margin over normal cells.
Read the full history of PNC-27Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for PNC-27, on one page.